During the corresponding time, Verastem Inc recorded a revenue increase by 1775.43 % year on year, sequentially revenue grew by 114.65 %. While revenue at the Verastem Inc 's corporate clients
Verastem Inc's Comment on Sales, Marketing and Customers
The company serves customers and markets including the Veterans Administration (VA), Department of Defense (including military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, Public Health Service (PHS), hospitals serving financially needy patients, community health clinics, and other entities receiving health services grants from the PHS. Its markets also include federal, state, and foreign governments that implement cost containment programs affecting drug pricing and reimbursement. Specific market segments include Medicaid Drug Rebate Program and Medicare Part B purchasers, as well as national health insurance systems in European Union member states that regulate drug reimbursement and pricing.
Verastem Oncology s Groundbreaking Advancements in Ovarian Cancer Treatment: FDA Accepts NDA for Avutometinib and Defactinib In a significant stride towards enhancing therapeutic options for patients suffering from recurrent low-grade serous ovarian cancer (LGSOC), Verastem Oncology, a biopharmaceutical company dedicated to the development of innovative medicines for cancer treatment, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for avutometinib in combination with defactinib . This NDA has been designated under the accelerated approval pathway, highlighting the urgent need for effective treatments in this challenging oncology spa...
Unveiling a New Chapter in Cancer Treatment: Verastem Oncology s Breakthrough Therapy for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer The world of oncology is complex, fraught with battles against some of the most formidable foes to human health. Yet, amidst the ever-changing landscape of cancer research, there are moments of profound hope moments that shine brightly with the promise of transformative care. Recently, Verastem Oncology, a visionary in the field of cancer therapeutics, kindled such hope with an announcement that could influence the lives of thousands of women worldwide. Its latest breakthrough has taken a pivotal step along the drug approval journey, marking a significant milestone i...
Verastem Oncology Unveils Promising Results from RAMP 201 Trial for Ovarian Cancer Treatment at IGCS 2024 Annual MeetingBOSTON Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to developing innovative therapies for cancer patients, has announced encouraging updated results from their RAMP 201 (ENGOT-ov60/GOG3052) Phase 2 clinical trial. The trial evaluates the efficacy of combining avutometinib, an oral RAF/MEK clamp, with defactinib, an oral selective FAK inhibitor, in patients suffering from recurrent low-grade serous ovarian cancer (LGSOC). These findings were presented as a late-breaking abstract at the 2024 International Gynecologic Cancer Society (IGCS) Annual Meeting.In the R...
Pomerantz LLP, a renowned law firm specializing in securities litigation, has recently announced that it is investigating claims on behalf of investors of Verastem, Inc. This article examines the allegations against the Company, the potential impact on shareholders, and the contact details for affected investors to reach out to Pomerantz LLP.Verastem, Inc. (NASDAQ: VSTM):Verastem, Inc., a biopharmaceutical company, is currently under scrutiny for possible infringements on the rights of its investors. Pomerantz LLP is conducting a thorough investigation into these claims. Notably, investors who may have suffered financial losses due to the alleged misconduct of Verastem are advised to contact Danielle Peyton,...
BOSTON Verastem Oncology (Nasdaq: VSTM), an innovative biopharmaceutical company dedicated to developing and advancing new medicines for cancer patients, today heralded the initial interim safety and efficacy results from their ongoing RAMP 205 Phase 1/2 clinical trial. This groundbreaking trial evaluates the effects of avutometinib in combination with defactinib, gemcitabine, and nab-paclitaxel for the first-line treatment of metastatic pancreatic cancer. The encouraging news arrives on the heels of the company s latest business updates and first quarter financial report for 2024, reflecting a period of significant milestones and promising advancements. Breakthrough in Metastatic Pancreatic Cancer Trial ...
The new face of biopharmaceutical industry, Verastem Oncology, known for its dedication in revolutionizing cancer treatments, is stepping up in its game. As per official reports, it recently presented promising business updates and disclosed its first quarter financial results of 2024. Committed to making continuous strides in oncology, Verastem Oncology is prominently featured on Nasdaq under the symbol VSTM. The company’s business updates and financial results for the first quarter that ended on March 31, 2024, significantly create a new chapter in its journey of combating cancers, delineate the path it charts, and point towards the transformative milestones.In the first quarter of 2024, a significant vi...
Verastem Oncology, a renowned biopharmaceutical company dedicated to developing innovative treatments for cancer patients, has recently released its financial results for the first quarter of 2024. The company has also achieved a significant milestone by obtaining FDA Orphan Drug Designation for their avutometinib and defactinib combination therapy. This designation acknowledges the unique nature of recurrent low-grade serous ovarian cancer and highlights the potential of this therapy in addressing this specific form of cancer.Financial Performance:Verastem Oncology s financial results for Q1 2024 demonstrate a positive trajectory for the company. The specific figures in terms of revenue, expenses, and net i...
Verastem Inc’s Comment on Sales, Marketing and Customers
The company serves customers and markets including the Veterans Administration (VA), Department of Defense (including military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, Public Health Service (PHS), hospitals serving financially needy patients, community health clinics, and other entities receiving health services grants from the PHS. Its markets also include federal, state, and foreign governments that implement cost containment programs affecting drug pricing and reimbursement. Specific market segments include Medicaid Drug Rebate Program and Medicare Part B purchasers, as well as national health insurance systems in European Union member states that regulate drug reimbursement and pricing.
Sources:
Verastem Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Verastem Inc’s corporate clients.
For your research, we’ve provided 9 tables on Verastem Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
62.57 %